GSK plc DRC (GSK)

NYSE


	Symbol		Exchange		Currency
	GSK		NYSE		USD	Real-time
	GSKl		BATS Europe		GBP	Delayed
	GLAXF		OTC Markets		USD	Delayed
	GSK		London		GBP	Real-time
	GSKN		Mexico		MXN	Delayed
	GS71		Xetra		EUR	Delayed
	GS71		Frankfurt		EUR	Delayed
	GS71		TradeGate		EUR	Delayed
	GS70y		Frankfurt		EUR	Delayed
	GSKm		Buenos Aires		ARS	Delayed
	G1SK34		B3		BRL	Delayed

Currency in USD

Disclaimer

38.83

-0.38(-0.97%)

Closed11/10

After Hours

38.79-0.04(-0.10%)

11/10

Fair Value

Day's Range

38.63

39.15

52 wk Range

33.67

45.92

GSK Income Statement

Featured here, the Income Statement (earnings report) for GSK plc DRC, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

33,754

24,354

24,696

29,324

30,328

Total Revenues Growth

+9.52%

-27.85%

+1.4%

+18.74%

+3.42%

Cost Of Revenues

10,792

7,321

8,033

9,407

8,388

Gross Profit

22,962

17,033

16,663

19,917

21,940

Gross Profit Growth

+8.79%

-25.82%

-2.17%

+19.53%

+10.16%

Gross Profit Margin %

68.03%

69.94%

67.47%

67.92%

72.34%

Other Operating Expenses, Total

14,761

10,983

11,029

12,595

13,537

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+8.44%	-25.59%	+0.42%	+14.2%	+7.48%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4,405	4,397	4,627	5,153	5,823
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	10,962	7,041	6,784	8,179	9,156
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-606	-455	-382	-737	-1,442

Operating Income

8,201

6,050

5,634

7,322

8,403

Operating Income Growth

+9.42%

-26.23%

-6.88%

+29.96%

+14.76%

EBIT Margin %

24.3%

24.84%

22.81%

24.97%

27.71%

Net Interest Expenses

-798

-818

-749

-757

-602

Net Interest Expenses Growth

-17.01%

-2.51%

+8.44%

-1.07%

+20.48%

Interest Expense, Total

-877

-844

-762

-819

-710

Interest And Investment Income

79

26

13

62

108

Other Non Operating Expenses, Total

62

9

27

-48

-80

EBT, Excl. Unusual Items

7,465

5,241

4,912

6,517

7,721

Gain (Loss) On Sale Of Assets

541

2,857

552

215

61

Other Unusual Items, Total

-661

-1,508

-1,442

-1,039

-1,215

EBT, Incl. Unusual Items

6,221

5,170

3,599

5,628

6,064

EBT, Incl. Unusual Items Growth

+29.6%

-16.89%

-30.39%

+56.38%

+7.75%

EBT, Incl. Unusual Items Margin

18.43%

21.23%

14.57%

19.19%

19.99%

Income Tax Expense

953

67

83

707

756

Net Income to Company

5,268

5,979

4,585

15,416

5,308

Minority Interest

-623

-230

-200

-460

-380

Net Income

4,645

5,749

4,385

14,956

4,928

Net Income Growth

+28.21%

+23.77%

-23.73%

+241.07%

-67.05%

Net Income Margin %

13.76%

23.61%

17.76%

51%

16.25%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

4,645

4,873

3,316

4,461

4,928

Basic EPS - Continuing Operations

1.17

1.22

0.83

1.11

1.22

Basic EPS - Continuing Operations Growth

+27.35%

+4.29%

-32.33%

+33.76%

+9.76%

Diluted EPS - Continuing Operations

1.16

1.21

0.82

1.09

1.2

Diluted EPS - Continuing Operations Growth

+27.02%

+4.45%

-32.34%

+33.5%

+9.8%

Basic Weighted Average Shares Outstanding

3,957.6

3,981

4,003

4,026

4,052

Diluted Weighted Average Shares Outstanding

4,012.8

4,030

4,052

4,084

4,111

Dividend Per Share

1

1

1

0.61

0.58

Dividend Per Share Growth

0%

0%

0%

-38.75%

-5.31%

EBITDA

10,321

8,100

7,756

9,089

10,304

EBITDA Growth

+10.37%

-21.52%

-4.25%

+17.19%

+13.37%

EBITDA Margin %